Supplementary Figure 1

In vitro treatment of Hepa129 tumor cells with Belinostat does not modify expression of T-cell stimulatory/inhibitory molecules and recognition by antitumor T-cells. Hepa129 tumor cells were cultured with Belinostat (0.5 µM) and 24 h later they were harvested. Expression of MHC-I H-2 Kk, CD86 and PD-L1 molecules was determined by flow cytometry (a-c). Recognition of tumor cells by tumor-specific T-cells was carried out by incubating 5 x 10^4 Belinostat-treated tumor cells with 5 x 10^5 splenocytes obtained from mice which had rejected their tumors (d).
Supplementary Figure 2

Leukocytic infiltration and expression of PD-L1 on infiltrating and tumor cells. Mice with 8 mm tumors received different treatments for 7 days. Tumors were obtained and the proportion of infiltrating CD45+ leukocytes (a) and expression of PD-L1 in CD45+ (b) and CD45− (c) cells were analyzed by flow cytometry.
Supplementary Figure 3
Mean plasma concentration of Belinostat administered through different routes. Mice received a single Belinostat administration (50 mg/kg) through different routes and plasma concentrations were measured at different time points.